These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11049023)

  • 1. Novel therapeutic agents for the treatment of myelodysplastic syndromes.
    Cheson BD; Zwiebel JA; Dancey J; Murgo A
    Semin Oncol; 2000 Oct; 27(5):560-77. PubMed ID: 11049023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M
    Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome.
    Foss FM
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):573-84. PubMed ID: 15494295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
    Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
    Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
    Klimek VM; Fircanis S; Maslak P; Guernah I; Baum M; Wu N; Panageas K; Wright JJ; Pandolfi PP; Nimer SD
    Clin Cancer Res; 2008 Feb; 14(3):826-32. PubMed ID: 18245545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating novel agents in the treatment of myelodysplastic syndromes.
    Anargyrou K; Vassilakopoulos TP; Angelopoulou MK; Terpos E
    Leuk Res; 2010 Jan; 34(1):6-17. PubMed ID: 19656566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
    Leone G; Teofili L; Voso MT; Lübbert M
    Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
    Cilloni D; Messa E; Messa F; Carturan S; Defilippi I; Arruga F; Rosso V; Catalano R; Bracco E; Nicoli P; Saglio G
    Ann N Y Acad Sci; 2006 Nov; 1089():411-23. PubMed ID: 17261784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
    Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supportive care, growth factors, and new therapies in myelodysplastic syndromes.
    Hellström-Lindberg E; Malcovati L
    Blood Rev; 2008 Mar; 22(2):75-91. PubMed ID: 18068281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies.
    Gore SD
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S30-5. PubMed ID: 16341238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of angiogenesis in patients with myelodysplastic syndrome.
    Estey EH
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):623-39. PubMed ID: 15494299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes.
    Aguayo A
    Curr Hematol Rep; 2004 May; 3(3):184-91. PubMed ID: 15087066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
    Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
    Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents for the management of myelodysplastic syndromes.
    Meletis J; Viniou N; Terpos E
    Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
    Kurzrock R; Cortes J; Kantarjian H
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):20-4. PubMed ID: 12447848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of signaling in myelodysplastic syndrome.
    Gore SD
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):613-22. PubMed ID: 15494298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
    Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.
    Morgan MA; Reuter CW
    Ann Hematol; 2006 Mar; 85(3):139-63. PubMed ID: 16391911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.